TAVR Patients Requiring Anticoagulation: Direct Oral Anticoagulant or Vitamin K Antagonist?

Archive ouverte

Didier, Romain | Lhermusier, Thibault | Auffret, Vincent | Eltchaninoff, Hélène | Le Breton, Herve | Cayla, Guillaume | Commeau, Philippe | Collet, J. P., Philippe | Cuisset, Thomas | Dumonteil, Nicolas | Verhoye, J. P., Philippe | Beurtheret, Sylvain | Lefevre, Thierry | Teiger, Emmanuel | Carrié, Didier | Himbert, Dominique | Albat, Bernard | Cribier, Alain | Sudre, Arnaud | Blanchard, Didier | Bar, Olivier | Rioufol, Gilles | Collet, Frédéric | Houel, Remi | Labrousse, Louis | Meneveau, Nicolas | Ghostine, Said | Manigold, Thibaut | Guyon, Philippe | Delepine, Stephane | Favereau, Xavier | Souteyrand, Geraud | Ohlmann, Patrick | Doisy, Vincent | Beygui, Farzin | Gommeaux, Antoine | Claudel, Jean-Philippe | Bourlon, Francois | Bertrand, Bernard | Iung, Bernard | Gilard, Martine

Edité par CCSD ; Elsevier/American College of Cardiology -

International audience. OBJECTIVES: Using French transcatheter aortic valve replacement (TAVR) registries linked with the nationwide administrative databases, the study compared the rates of long-term mortality, bleeding, and ischemic events after TAVR in patients requiring oral anticoagulation with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs). BACKGROUND: The choice of optimal drug for anticoagulation after TAVR remains debated. METHODS: Data from the France-TAVI and FRANCE-2 registries were linked to the French national health single-payer claims database, from 2010 to 2017. Propensity score matching was used to reduce treatment-selection bias. Two primary endpoints were death from any cause (efficacy) and major bleeding (safety). RESULTS: A total of 24,581 patients who underwent TAVR were included and 8,962 (36.4%) were treated with OAC. Among anticoagulated patients, 2,180 (24.3%) were on DOACs. After propensity matching, at 3 years, mortality (hazard ratio [HR]: 1.37; 95% confidence interval [CI]: 1.12-1.67; P \textless 0.005) and major bleeding including hemorrhagic stroke (HR: 1.64; 95% CI: 1.17-2.29; P \textless 0.005) were lower in patients on DOACs compared with those on VKAs. The rates of ischemic stroke (HR: 1.32; 95% CI: 0.81-2.15; P = 0.27) and acute coronary syndrome (HR: 1.17; 95% CI: 0.68-1.99; P = 0.57) did not differ among groups. CONCLUSIONS: In these large multicenter French TAVR registries with an exhaustive clinical follow-up, the long-term mortality and major bleeding were lower with DOACs than VKAs at discharge. The present study supports preferential use of DOACs rather than VKAs in patients requiring oral anticoagulation therapy after TAVR.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion